Alexandria Real Estate Equities has contributed to a $76m round for KSQ, which is developing genomics-focused oncology and immunology drugs.
US-based genomic drug developer KSQ Therapeutics emerged from stealth today with $76m in financing from investors including life sciences real estate trust Alexandria Real Estate Equities.
The round was led by life sciences company builder Flagship Pioneering and also featured venture capital firms Polaris Partners and Arch Venture Partners.
Founded in 2015, KSQ is working on drugs based on a precision genomics platform it has developed called Crispromics, with which it aims to quickly and effectively identify therapeutic nodes that…
